Medication info

Stamet tablet 50/500 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Sitagliptin Phosphate Hydrate›64.25mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Dong Sung Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablets
Packaging
56 tablets (14 tablets/PTP x 4)
Approval status
Expired

MFDS item code 201505855 · Approved 2015.08.20

This product's status changed to Expired on 2025.08.20. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this medicine should be determined according to each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The starting dose of this medicine should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who have difficulty achieving adequate glycemic control with monotherapy, or who cannot achieve adequate glycemic control with sitagliptin monotherapy, the starting dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Take This Medicine). 2. Patients receiving metformin: - The recommended starting dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient’s current metformin dose. - Patients switching to this medicine from concomitant sitagliptin and metformin therapy may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The starting dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The starting dose of metformin should take the patient’s blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medicine is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medicine).

Ingredients

Manufacturer
Dong Sung Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps regulate blood sugar levels in patients with type 2 diabetes by using sitagliptin and metformin together. It is prescribed as an adjunct to diet and exercise in patients who need support. Through this, blood sugar levels can be effectively improved.

How to take

Adult dose

In antidiabetic therapy, the dose of this medicine should be determined according to each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The starting dose of this medicine should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who have difficulty achieving adequate glycemic control with monotherapy, or who cannot achieve adequate glycemic control with sitagliptin monotherapy, the starting dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Take This Medicine). 2. Patients receiving metformin: - The recommended starting dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient’s current metformin dose. - Patients switching to this medicine from concomitant sitagliptin and metformin therapy may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The starting dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The starting dose of metformin should take the patient’s blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medicine is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medicine).

Precautions

This medication contains sitagliptin and metformin, which help in blood glucose control for type 2 diabetes. Firstly, this medication can cause rare but severe allergic reactions due to the sitagliptin component, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur within 3 months of administration, discontinue use immediately and consult a doctor. Additionally, serious side effects such as pancreatitis, which is inflammation of the pancreas, have been reported. If symptoms like abdominal pain, nausea, or vomiting occur, visit a hospital immediately. Although rare, the metformin component can cause a serious metabolic disorder called lactic acidosis, so if symptoms like sudden fatigue, muscle pain, difficulty breathing, or abdominal pain appear, it is important to stop taking the medication immediately and inform healthcare personnel. This medication should not be given to patients with significantly impaired kidney function, severe infections, dehydration, or heart failure. Particularly, before and after tests using radiocontrast iodine, it is safe to stop taking this medication at least 48 hours prior to the test and resume only after confirming that kidney function is normal. It is recommended that this medication not be used by women who are pregnant or may become pregnant, or by women who are breastfeeding. Also, irregular eating, extreme exercise, or the use of other medications can increase the risk of hypoglycemia or lactic acidosis, so caution is necessary. During the course of treatment with this medication, regular monitoring of kidney function, blood tests, and vitamin B12 levels is required, and excessive alcohol consumption should be avoided as it may increase the risk of lactic acidosis. If surgery is approaching, discontinue taking this medication 48 hours before the procedure and only restart after confirming normal kidney function post-surgery. Taking this medication in conjunction with other antidiabetic agents may increase the risk of hypoglycemia, so be alert for signs of hypoglycemia and adjust the doses of other medications if necessary. Finally, if severe joint pain or skin blistering occurs while taking this medication, inform your doctor immediately and seek treatment.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 25 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • vitamin B12 deficiency
  • rash
  • urticaria
  • cutaneous vasculitis
  • elevated liver enzyme levels
  • acute renal failure
  • dyspnea
  • unstable angina
  • dizziness
  • decreased appetite
  • itching
  • weight loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a container that is tightly sealed to prevent air ingress, and is safely stored at a temperature between 1 to 30 degrees Celsius. This way of storage helps maintain the medication's efficacy and safety.

Appearance and packaging

Appearance

Pink oval film-coated tablets

Package unit

56 tablets (14 tablets/PTP x 4)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.